Zhenyu Yan

Dr. Zhenyu Yan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HCHuacong Cai
Huacong Cai
JWJishi Wang
Jishi Wang
ZYZhenyu Yan
Zhenyu Yan
HZHu Zhou
Hu Zhou
ZLZhenyu Li
Zhenyu Li
SWShujie Wang
Shujie Wang
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.

1 June 2016
Verified
Journal Article
Closed access
XHXiao-Yang Hao
Xiao-Yang Hao
LWLin-Hong Wang
Lin-Hong Wang
YXYan-Yan Xie
Yan-Yan Xie
WQWen-Yue Qi
Wen-Yue Qi
SZSong Zhang
Song Zhang
NCNai-Yao Chen
Nai-Yao Chen

5 November 2026 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
JLJia-Qi Liu
Jia-Qi Liu
LSLin Sun
Lin Sun
YXYan-Yan Xie
Yan-Yan Xie
LJLe Jiang
Le Jiang
JXJun-Jie Xu
Jun-Jie Xu
XLXinguang Liu
Xinguang Liu
Elderly patients with primary immune thrombocytopenia (ITP) are particularly vulnerable to bleeding and corticosteroid-related toxicity, and management is

1 June 2020
Verified
Journal Article
Closed access
YZYi-Wen Zhu
Yi-Wen Zhu
YXYan-Yan Xie
Yan-Yan Xie
XWXin Wang
Xin Wang
JLJie Li
Jie Li
LWLin-Hong Wang
Lin-Hong Wang
ZYZhenyu Yan
Zhenyu Yan

16 June 2026 in Thrombosis Research
Verified
Journal Article
Closed access
LZLisha Zhao
Lisha Zhao
YXYanyan Xie
Yanyan Xie
ZYZhenyu Yan
Zhenyu Yan

1 October 2020
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
LWLin-Hong Wang
Lin-Hong Wang
YXYan-Yan Xie
Yan-Yan Xie
JLJie Li
Jie Li
ZYZhenyu Yan
Zhenyu Yan